Personalized Antiplatelet Therapy in CAD Patients

Conditions

Coronary Artery Disease

Keywords

CYP2C19

Brief summary

This study is a prospective, no-randomized, single-center study performed on 15000 consecutive coronary artery patients from Dec. 2016 to Oct. 2021. All these patients were detected CYP2C19 genotype. The antiplatelet treatment was recorded according to the therapy actually adopted by the patients.

Ting‐Ting Wu, Ying Pan, Ying-Ying Zheng, Zhilong Wang, Chang‐Jiang Deng et al. (7 authors)

Lipids in Health and Disease2024-09-102 citations

10.1186/s12944-024-02273-z

Association between extremely high prognostic nutritional index and all-cause mortality in patients with coronary artery disease: secondary analysis of a prospective cohort study in China

Tingting Wu, Ying Pan, Xiao-Yu Zhi, Chang‐Jiang Deng, Shun Wang et al. (10 authors)

BMJ Open2024-06-019 citations

10.1136/bmjopen-2023-079954

Association between the C-Reactive Protein–Albumin–Lymphocyte (CALLY) Index and Adverse Clinical Outcomes in CAD Patients after PCI: Findings of a Real-World Study

Ying Pan, Tingting Wu, Chang‐Jiang Deng, Zhi-Hui Jiang, Yi Yang et al. (11 authors)

Reviews in Cardiovascular Medicine2024-03-2513 citations

10.31083/j.rcm2504111

Serum Globulin to Albumin Ratio as a Novel Predictor of Adverse Clinical Outcomes in Coronary Artery Disease Patients Who Underwent PCI

Sifan Wang, Tingting Wu, Ying‐Ying Zheng, Xian‐Geng Hou, Haitao Yang et al. (7 authors)

Reviews in Cardiovascular Medicine2023-10-072 citations

10.31083/j.rcm2410278

Cystatin C to Left Ventricular Ejection Fraction Ratio as a Novel Predictor of Adverse Outcomes in Patients with Coronary Artery Disease: A Prospective Cohort Study

Yi Ning, Kai-Yang Wang, Min Xuan, Xian‐Geng Hou, Tingting Wu et al. (7 authors)

Reviews in Cardiovascular Medicine2023-09-18

10.31083/j.rcm2409260

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

1.Aged \>18 years old; 2. Coronary angiography confirmed that there was at least one coronary artery stenosis \>70%; or the degree of stenosis of the left main artery stenosis \>50%; 3. At least one clinical phenotype of coronary heart disease is present: stable angina or acute coronary syndrome 4.To be able to sign informed consent.

Exclusion criteria

1. Combined with severe valvular heart disease; 2. Combined with severe congenital heart disease; 3. Combined hyperthyroidism, anemia and other high-powered heart disease; 4. With pulmonary heart disease; 5\. With hypertrophic obstructive cardiomyopathy; 6. Severe hypotension (SBP \<90mmHg or DBP \<60mmHg at enrollment); 7. Liver dysfunction (defined as ALT or total bilirubin is greater than the normal upper limit of 3 times); 8. Renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit); 9. High-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases; 10. active peptic ulcer and skin ulcers; 11. A patient who is allergic to clopidogrel, Ticagrelor, or aspirin; 12. Patients with a history of cardiogenic shock within two weeks; 13. pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age; 14. In the past 3 months participated in other clinical researchers; 15. Persons who do not have legal or legal competence; 16. Any condition that the investigator considers unsuitable for participation in the clinical study.

Design outcomes

Primary

Measure	Time frame	Description
Mortality	5 years	All-cause death and cardiac death
Net clinical adverse events	5 years	a composite of cardiac death, myocardial infarction (MI), revascularization, and bleeding (Bleeding Academic Research Consortium (BARC) definitions, type 2, 3, or 5),
bleeding events	5 years	BARC class 2 or higher bleeding events

Secondary

Measure	Time frame	Description
stent thrombosis	5 years	according to the Academic Research Consortium criteria
myocardial infarction	5 years	defined in accordance with the universal definition proposed in 2007
major adverse cardiovascular and cerebrovascular events (MACCE)	5 years	cardiac death, stroke, MI, stent thrombosis, or urgent revascularization
urgent revascularization	5 years	with persistent or increasing symptoms need to intervention
major adverse cardiovascular events (MACE)	5 years	defined as cardiac death, cardiac death, MI, stent thrombosis, or urgent revascularization
stroke	5 years	including ischemic stroke and hemorrhage
all-cause death	5 years	all-cause death
cardiac death	5 years	death for cardiac cause

Outcome results